{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"description":"Number of participants with abnormal laboratory values and/or adverse events","groups":[{"description":"Induction: Daunorubicin, cytarabine and gilteritinib. Depending on response, second cycle of Induction may be given.\n\nConsolidation: High-dose cytarabine and gilteritinib.\n\nGilteritinib: Induction: 120 mg orally daily x 14 days starting on day 8\n\nConsolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)\n\nDaunorubicin: First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3\n\nSecond Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3\n\nCytarabine: Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1\n\nSecond Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1\n\nConsolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles","id":"OG000","title":"Arm A"},{"description":"Induction: Daunorubicin, cytarabine and midostaurin. Depending on response, second cycle of Induction may be given.\n\nConsolidation: High-dose cytarabine and midostaurin.\n\nMidostaurin: Induction: 50 mg orally twice daily x 14 days beginning on day 8\n\nConsolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)\n\nDaunorubicin: First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3\n\nSecond Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3\n\nCytarabine: Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1\n\nSecond Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1\n\nConsolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles","id":"OG001","title":"Arm B"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"10 months","title":"Number of Participants Treatment-related Adverse Events as Assessed by CTCAE v5.0","type":"SECONDARY","unitOfMeasure":"Participants"}